Biologic manufacturers could face a wave of enforcement actions against behavior that impedes the marketing of biosimilars as the US Food and Drug Administration and Federal Trade Commission are teaming up to promote competition in biologics markets.
FDA And FTC Join Forces On Biosimilars
Teaming Up To Eliminate Barriers To Biosimilar Competition
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
